<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4864301</article-id><article-id pub-id-type="pmid">27167126</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0155139</article-id><article-id pub-id-type="publisher-id">PONE-D-15-45576</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Bacterial Pathogens</subject><subj-group><subject>Pseudomonas Aeruginosa</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Bacterial Pathogens</subject><subj-group><subject>Pseudomonas Aeruginosa</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Pseudomonas</subject><subj-group><subject>Pseudomonas Aeruginosa</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Staphylococcus</subject><subj-group><subject>Staphylococcus Aureus</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Bacterial Pathogens</subject><subj-group><subject>Staphylococcus</subject><subj-group><subject>Staphylococcus Aureus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Bacterial Pathogens</subject><subj-group><subject>Staphylococcus</subject><subj-group><subject>Staphylococcus Aureus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibacterials</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial Control</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibacterials</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Structures and Organelles</subject><subj-group><subject>Cell Membranes</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial Control</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Bacterial Pathogens</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Bacterial Pathogens</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject><subj-group><subject>Polymyxins</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial Control</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject><subj-group><subject>Polymyxins</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial Control</subject><subj-group><subject>Antimicrobial Resistance</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Antimicrobial Resistance</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Elucidation of the Mode of Action of a New Antibacterial Compound Active against <italic>Staphylococcus aureus</italic> and <italic>Pseudomonas aeruginosa</italic></article-title><alt-title alt-title-type="running-head">Mode of Action of the New Antibacterial SPI031</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gerits</surname><given-names>Evelien</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Blommaert</surname><given-names>Eline</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lippell</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>O&#x02019;Neill</surname><given-names>Alex J.</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Weytjens</surname><given-names>Bram</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>De Maeyer</surname><given-names>Dries</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fierro</surname><given-names>Ana Carolina</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Marchal</surname><given-names>Kathleen</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Marchand</surname><given-names>Arnaud</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chaltin</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Spincemaille</surname><given-names>Pieter</given-names></name><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>De Brucker</surname><given-names>Katrijn</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Thevissen</surname><given-names>Karin</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cammue</surname><given-names>Bruno P. A.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff008"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Swings</surname><given-names>Toon</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liebens</surname><given-names>Veerle</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fauvart</surname><given-names>Maarten</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff009"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Verstraeten</surname><given-names>Natalie</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Michiels</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Centre of Microbial and Plant Genetics, KU Leuven, Leuven, Belgium</addr-line></aff><aff id="aff002"><label>2</label><addr-line>School of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom</addr-line></aff><aff id="aff003"><label>3</label><addr-line>Department of Information Technology (INTEC, iMINDS), U.Ghent, Ghent, Belgium</addr-line></aff><aff id="aff004"><label>4</label><addr-line>Department of Plant Biotechnology and Bioinformatics, U.Ghent, Ghent, Belgium</addr-line></aff><aff id="aff005"><label>5</label><addr-line>CISTIM Leuven vzw, Bio-Incubator, KU Leuven, Leuven, Belgium</addr-line></aff><aff id="aff006"><label>6</label><addr-line>Centre for Drug Design and Discovery (CD3), Research and Development, KU Leuven, Leuven, Belgium</addr-line></aff><aff id="aff007"><label>7</label><addr-line>Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium</addr-line></aff><aff id="aff008"><label>8</label><addr-line>Department of Plant Systems Biology, VIB, Ghent, Belgium</addr-line></aff><aff id="aff009"><label>9</label><addr-line>imec, Smart Systems and Emerging Technologies Unit, Department of Life Science Technologies, Leuven, Belgium</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Seleem</surname><given-names>Mohamed N.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Purdue University, UNITED STATES</addr-line></aff><author-notes><fn fn-type="conflict" id="coi001"><p><bold>Competing Interests: </bold>MF is a researcher at imec. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: EG AL AJO KDB KT BPAC VL MF NV JM. Performed the experiments: EG EB AL PS. Analyzed the data: EG EB AL BW DDM ACF TS. Contributed reagents/materials/analysis tools: AM PC. Wrote the paper: EG NV JM. Revision of the manuscript: AJO KM KDB KT BPAC VL MF NV JM.</p></fn><corresp id="cor001">* E-mail: <email>Jan.Michiels@biw.kuleuven.be</email></corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><issue>5</issue><elocation-id>e0155139</elocation-id><history><date date-type="received"><day>16</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>25</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 Gerits et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Gerits et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0155139.pdf"/><abstract><p>Nosocomial and community-acquired infections caused by multidrug resistant bacteria represent a major human health problem. Thus, there is an urgent need for the development of antibiotics with new modes of action. In this study, we investigated the antibacterial characteristics and mode of action of a new antimicrobial compound, SPI031 (N-alkylated 3, 6-dihalogenocarbazol 1-(sec-butylamino)-3-(3,6-dichloro-9H-carbazol-9-yl)propan-2-ol), which was previously identified in our group. This compound exhibits broad-spectrum antibacterial activity, including activity against the human pathogens <italic>Staphylococcus aureus</italic> and <italic>Pseudomonas aeruginosa</italic>. We found that SPI031 has rapid bactericidal activity (7-log reduction within 30 min at 4x MIC) and that the frequency of resistance development against SPI031 is low. To elucidate the mode of action of SPI031, we performed a macromolecular synthesis assay, which showed that SPI031 causes non-specific inhibition of macromolecular biosynthesis pathways. Liposome leakage and membrane permeability studies revealed that SPI031 rapidly exerts membrane damage, which is likely the primary cause of its antibacterial activity. These findings were supported by a mutational analysis of SPI031-resistant mutants, a transcriptome analysis and the identification of transposon mutants with altered sensitivity to the compound. In conclusion, our results show that SPI031 exerts its antimicrobial activity by causing membrane damage, making it an interesting starting point for the development of new antibacterial therapies.</p></abstract><funding-group><funding-statement>This work was supported by the European Commission&#x02019;s Seventh Framework Programme (FP7/2007-2013) under the grant agreement COATIM (project n&#x000b0; 278425), the Interuniversity Attraction Poles Programme initiated by the Belgian Science Policy Office and by the FWO (grants G.0413.10, G.0471.12N, G0B2515N to JM). KT acknowledges the receipt of a mandate of the &#x02018;Industrial Research Fund&#x02019; of KU Leuven (IOFm/05/022). imec provided support in the form of salaries for author MF. The funders did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the &#x02018;author contributions&#x02019; section.</funding-statement></funding-group><counts><fig-count count="7"/><table-count count="0"/><page-count count="17"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>The entire set of RNAseq data is available from the public database ArrayExpress (Accession Number E-MTAB-4691).</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>The entire set of RNAseq data is available from the public database ArrayExpress (Accession Number E-MTAB-4691).</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Bacterial infections are among the most serious threats to human health. Millions of people acquire such infections each year, leading to increased mortality rates worldwide and an economic burden on society [<xref rid="pone.0155139.ref001" ref-type="bibr">1</xref>]. The Gram-positive pathogen <italic>Staphylococcus aureus</italic> is one of the major causes of nosocomial and community-acquired infections [<xref rid="pone.0155139.ref002" ref-type="bibr">2</xref>]. This bacterium accounts for 12.3% of all nosocomial infections in Europe, resulting in bacteremia and surgical wound infections, and is the main cause of implant-related infections [<xref rid="pone.0155139.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0155139.ref004" ref-type="bibr">4</xref>]. Infections caused by community-acquired <italic>S</italic>. <italic>aureus</italic> can range from minor skin and tissue infections to progressive pneumonia [<xref rid="pone.0155139.ref005" ref-type="bibr">5</xref>]. The emergence of methicillin-resistant <italic>S</italic>. <italic>aureus</italic> has severely complicated the treatment of such infections. Currently, glycopeptide antibiotics such as vancomycin are often used to treat both methicillin-susceptible and methicillin-resistant infections [<xref rid="pone.0155139.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0155139.ref007" ref-type="bibr">7</xref>]. However, in the past few years, there have been several reports of vancomycin-resistant <italic>S</italic>. <italic>aureus</italic> infections [<xref rid="pone.0155139.ref008" ref-type="bibr">8</xref>&#x02013;<xref rid="pone.0155139.ref010" ref-type="bibr">10</xref>].</p><p>The Gram-negative bacterium <italic>Pseudomonas aeruginosa</italic> is another important pathogen that is frequently involved in nosocomial and community-acquired infections [<xref rid="pone.0155139.ref011" ref-type="bibr">11</xref>]. This pathogen is responsible for 8.9% of infections in European hospitals and is most commonly found in patients with cancer, cystic fibrosis or burn wounds [<xref rid="pone.0155139.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0155139.ref011" ref-type="bibr">11</xref>]. In addition, <italic>P</italic>. <italic>aeruginosa</italic> is the main causative Gram-negative agent in implant-related infections [<xref rid="pone.0155139.ref004" ref-type="bibr">4</xref>]. Community-acquired infections caused by this pathogen include ulcerative keratitis, otitis externa and skin/soft tissue infections [<xref rid="pone.0155139.ref011" ref-type="bibr">11</xref>]. <italic>P</italic>. <italic>aeruginosa</italic> infections are usually treated with antibiotics such as &#x003b2;-lactams, aminoglycosides, or quinolones [<xref rid="pone.0155139.ref012" ref-type="bibr">12</xref>]. Alarmingly, multiple multidrug resistant strains of <italic>P</italic>. <italic>aeruginosa</italic> have emerged during the last years, some of them displaying resistance even towards the last-resort antibiotic polymyxin B [<xref rid="pone.0155139.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0155139.ref013" ref-type="bibr">13</xref>].</p><p>Lately, it has become clear that multidrug resistance is spreading at a very fast rate [<xref rid="pone.0155139.ref001" ref-type="bibr">1</xref>]. Unfortunately, only 5 new classes of antibiotics were marketed since 2000, and most of these do not work against Gram-negative pathogens [<xref rid="pone.0155139.ref014" ref-type="bibr">14</xref>]. Thus, there exists a pressing need for the development of new antibacterial agents. Recently, we identified a new antibacterial compound SPI031 (N-alkylated 3, 6-dihalogenocarbazol 1-(sec-butylamino)-3-(3,6-dichloro-9H-carbazol-9-yl)propan-2-ol) (<xref ref-type="fig" rid="pone.0155139.g001">Fig 1</xref>) with activity against a variety of bacteria, including <italic>Escherichia coli</italic> and the human pathogens <italic>S</italic>. <italic>aureus</italic>, <italic>P</italic>. <italic>aeruginosa</italic>, <italic>Staphylococcus epidermidis</italic> and <italic>Porphyromonas gingivalis</italic> [<xref rid="pone.0155139.ref015" ref-type="bibr">15</xref>]. In addition, we showed that the compound displays antifungal activity against <italic>Candida albicans</italic> [<xref rid="pone.0155139.ref016" ref-type="bibr">16</xref>]. Furthermore, we demonstrated that SPI031 has the clinical potential to be used as an antibacterial coating for implants, thereby reducing the incidence of implant-associated infections [<xref rid="pone.0155139.ref017" ref-type="bibr">17</xref>]. In the present study, we further investigated the antibacterial characteristics, including bactericidal activity and spontaneous resistance frequency, and mode of action of SPI031 using <italic>S</italic>. <italic>aureus</italic> and <italic>P</italic>. <italic>aeruginosa</italic> as model pathogens.</p><fig id="pone.0155139.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0155139.g001</object-id><label>Fig 1</label><caption><title>Structure of compound SPI031.</title></caption><graphic xlink:href="pone.0155139.g001"/></fig></sec><sec sec-type="materials|methods" id="sec002"><title>Material and Methods</title><sec id="sec003"><title>Bacterial strains and chemicals</title><p><italic>S</italic>. <italic>aureus</italic> SH1000 [<xref rid="pone.0155139.ref018" ref-type="bibr">18</xref>], <italic>P</italic>. <italic>aeruginosa</italic> PA14 [<xref rid="pone.0155139.ref019" ref-type="bibr">19</xref>], <italic>Klebsiella pneumoniae</italic> LMG 2095, <italic>Acinetobacter baumannii</italic> NCTC 13423, <italic>Enterobacter aerogenes</italic> LMG 2094, <italic>Enterococcus faecium</italic> LMG 8148 and <italic>Staphylococcus aureus</italic> ATCC 33591 were grown in 1/20 diluted trypticase soy broth (TSB, Becton Dickinson Benelux), TSB, lysogeny broth (LB) or on solid TSB medium containing 1.5% agar at 37&#x000b0;C.</p><p>SPI031 was supplied by CD3 (Leuven, Belgium) and stock solutions of 10 mM were prepared in dimethyl sulfoxide (DMSO). Vancomycin, polymyxin B, ofloxacin, tobramycin, ciprofloxacin, rifampicin, tetracycline, SDS, Triton X-100 and melittin were purchased from Sigma-Aldrich.</p></sec><sec id="sec004"><title>Minimum Inhibitory Concentration (MIC) Assay</title><p>MIC values were determined in 1/20 TSB with a broth microdilution procedure as previously described [<xref rid="pone.0155139.ref020" ref-type="bibr">20</xref>]. All MIC values calculated in the present study are listed in <xref ref-type="supplementary-material" rid="pone.0155139.s002">S1 Table</xref>.</p></sec><sec id="sec005"><title>Time-kill assay</title><p><italic>S</italic>. <italic>aureus</italic> and <italic>P</italic>. <italic>aeruginosa</italic> cells were cultured to exponential phase at 37&#x000b0;C in 1/20 TSB and challenged with antibacterial compounds at 1x and 4x MIC (see <xref ref-type="supplementary-material" rid="pone.0155139.s002">S1 Table</xref>). At different time points (0, 0.1, 0.5, 1, 2, 3, 4, 5, 24 h), a 200 &#x003bc;l aliquot was removed from each sample, washed, serially diluted in MgSO4 (10 mM) and plated on TSB agar for enumeration of colony forming units (CFU).</p></sec><sec id="sec006"><title>Spontaneous mutation frequency to resistance</title><p>The spontaneous mutation frequency of <italic>S</italic>. <italic>aureus</italic> and <italic>P</italic>. <italic>aeruginosa</italic> to resistance against different antibiotics was determined by plating bacterial inocula (10<sup>7</sup>&#x02212;10<sup>9</sup> CFU) on agar plates containing antibiotics at 5x MIC (see <xref ref-type="supplementary-material" rid="pone.0155139.s002">S1 Table</xref>). The number of viable cells present in the inoculum was determined by serial dilutions on drug-free agar plates. The mutation frequency was calculated by dividing the number of colonies formed on the plates after 48 h of incubation by the number of colonies on the drug-free plates. To confirm the results of this single-step mutation procedure, MIC tests were performed for all resistant mutants.</p></sec><sec id="sec007"><title>Whole genome sequencing of spontaneous resistant mutants</title><p>Spontaneous SPI031-resistant mutants of <italic>P</italic>. <italic>aeruginosa</italic> were generated as described above and three independent mutants were selected for further analysis. Resistance of selected mutants was verified by MIC determinations. Subsequently, genomic DNA from <italic>P</italic>. <italic>aeruginosa</italic> wild-type (WT) and the spontaneous resistant mutants was isolated using the DNeasy Blood &#x00026; Tissue Kit (Qiagen) following the manufacturer&#x02019;s protocol. DNA quantity and purity were assessed using a NanoDrop ND-1000. Samples were sent to the Genomics Core Facility of EMBL (Heidelberg, Germany) for whole genome sequencing on an Illumina HiSeq 2000 platform. Assembly of the reads and further analysis were performed using the CLC Genomics Workbench program v8.0. Genome sequences of spontaneous resistance mutants were aligned with the genome sequence of the WT to detect mutations. A coverage above 10x and cutoff frequency of 75% were considered for the detection of the mutations. Detected mutations were verified by PCR amplification and Sanger sequencing.</p></sec><sec id="sec008"><title>Macromolecular synthesis assay</title><p>Saturated cultures of <italic>S</italic>. <italic>aureus</italic> were diluted 1/100 in LB and grown to an OD<sub>600</sub> of 0.2 at 37&#x000b0;C. with aeration. Cultures were labeled by the addition of either [methyl-<sup>3</sup>H]thymidine, [5,6-<sup>3</sup>H]uridine or L-[G-<sup>3</sup>H]glutamine at 1 &#x003bc;Ci/ml to monitor synthesis of DNA, RNA, or proteins, respectively. After 10 min of incubation at 37&#x000b0;C, 100 &#x003bc;l of each culture was mixed with 100 &#x003bc;l of ice-cold 10% trichloroacetic acid (TCA) and stored on ice. The remainder of each culture was then treated with 4x MIC of SPI031, ciprofloxacin, rifampicin or tetracycline (see <xref ref-type="supplementary-material" rid="pone.0155139.s002">S1 Table</xref>). After 10 min of incubation, 100 &#x003bc;l of the treated cultures was mixed with an equal amount of 10% TCA and kept on ice for 30 min. TCA precipitates were collected under vacuum using a 96-well filter plate (96-well Unifilter GF/B, Perkin-Elmer), and filters onto which [5,6-<sup>3</sup>H]uridine-labelled samples had been deposited, were washed twice with 100 &#x003bc;l unlabeled uridine. Individual filters were then washed twice with 200 &#x003bc;l of 10% TCA each, and twice with 200 &#x003bc;l of acetic acid. Filter plates were dried, 25 &#x003bc;l scintillant (Microscint 20, Perking-Elmer) was added to each well, and radiolabeled incorporation was measured using a Chameleon multilabel plate scintillation counter (Hidex).</p></sec><sec id="sec009"><title>Carboxyfluorescein leakage assay</title><p>Carboxyfluorescein (CF) loaded into liposomes matching the lipid composition of the cytoplasmic membrane of <italic>S</italic>. <italic>aureus</italic> were prepared as described previously [<xref rid="pone.0155139.ref021" ref-type="bibr">21</xref>]. Aliquots (5 &#x003bc;l) of the liposomes were mixed with 95 &#x003bc;l liposome buffer (10 mM HEPES, 107 mM NaCl, pH 7.4) containing SPI031 at a final concentration equivalent to 1x MIC and 4x MIC against <italic>S</italic>. <italic>aureus</italic> SH1000 (see <xref ref-type="supplementary-material" rid="pone.0155139.s002">S1 Table</xref>). Samples were incubated at 37&#x000b0;C while shaking and CF release (&#x003bb;<sub>ex</sub> = 485 nm, &#x003bb;<sub>em</sub> = 520 nm) was measured 10, 60 and 180 min after incubation using a FLUOstar omega plate reader (BMG Labtech). The percentage of liposome integrity after treatment was determined relative to the amount of CF release after treatment of the liposomes with 0.5% Triton X-100 (corresponding to 0% liposome integrity).</p></sec><sec id="sec010"><title>Membrane permeability</title><p>SPI031-mediated permeabilization of the cytoplasmic membrane of both <italic>S</italic>. <italic>aureus</italic> and <italic>P</italic>. <italic>aeruginosa</italic> was measured using SYTOX green (Invitrogen, USA) as previously described [<xref rid="pone.0155139.ref022" ref-type="bibr">22</xref>], with some modification. Exponential-phase cells of <italic>S</italic>. <italic>aureus</italic> and <italic>P</italic>. <italic>aeruginosa</italic> grown in 1/20 TSB were washed and resuspended in phosphate-buffered saline to an OD<sub>595</sub> of 0.5. Cells were stained with 1 &#x003bc;M of SYTOX green dye and treated with SPI031 (0x, 0.25x, 0.5x and 1x MIC; see <xref ref-type="supplementary-material" rid="pone.0155139.s002">S1 Table</xref>). After a period of incubation (30 min for <italic>S</italic>. <italic>aureus</italic>, 15 min for <italic>P</italic>. <italic>aeruginosa</italic>), fluorescence was measured (&#x003bb;<sub>ex</sub> = 504 nm, &#x003bb;<sub>em</sub> = 523 nm) using a Synergy MX multimode reader.</p><p>Outer membrane permeability of <italic>P</italic>. <italic>aeruginosa</italic> was assessed using the hydrophobic fluorescent probe 1-N-phenylnaphthylamine (NPN, Sigma, USA) as previously described [<xref rid="pone.0155139.ref023" ref-type="bibr">23</xref>], with minor modifications. Briefly, <italic>P</italic>. <italic>aeruginosa</italic> cells were grown to exponential phase in 1/20 TSB, washed and resuspended to an OD<sub>595</sub> of 0.5 in buffer containing 5 mM HEPES, pH 7.2. Cells were mixed with NPN to a final concentration of 10 &#x003bc;M and treated with SPI031 (0x, 0.25x, 0.5x and 1x MIC; see <xref ref-type="supplementary-material" rid="pone.0155139.s002">S1 Table</xref>). Increase of fluorescence was measured immediately (&#x003bb;<sub>ex</sub> = 350 nm, &#x003bb;<sub>em</sub> = 420 nm) using a Synergy MX multimode reader (Biotek, Winooski, VT) at 37&#x000b0;C.</p><p>Fluorescence values were divided by corresponding OD<sub>595</sub> values to correct for cell densities. In addition, values were corrected for background fluorescence by subtracting the values of the untreated control cultures stained with NPN or SYTOX green.</p></sec><sec id="sec011"><title>Fluorescence microscopy</title><p>Exponential-phase cells of <italic>S</italic>. <italic>aureus</italic> and <italic>P</italic>. <italic>aeruginosa</italic> grown in 1/20 TSB were treated for 5 min with 0.5% DMSO (solvent control) or with 1x MIC of SPI031 (see <xref ref-type="supplementary-material" rid="pone.0155139.s002">S1 Table</xref>), centrifuged and stained with 10 &#x003bc;g/ml N-(3-triethylammoniumpropyl)-4-(p-diethylaminophenyl-hexatrienyl) pyridinium dibromide (FM 4&#x02013;64, Molecular Probes). Samples were spotted on 2% agarose pads for imaging. Images were captured using a Zeiss Axio imager Z1 fluorescence microscope equipped with a EC Plan-Neofluar 100x objective, using the FM 4&#x02013;64 channel (&#x003bb;<sub>ex</sub> = 540&#x02013;580 nm; &#x003bb;<sub>em</sub> = 593&#x02013;668 nm).</p></sec><sec id="sec012"><title>RNA sequencing and data analysis</title><p>Overnight cultures of <italic>P</italic>. <italic>aeruginosa</italic> were diluted 1/100 in 1/20 TSB and were grown for 3 h until late-exponential phase. Next, cells were treated for 5 min with 0.2x MIC of SPI031 (see <xref ref-type="supplementary-material" rid="pone.0155139.s002">S1 Table</xref>) or 1% DMSO (solvent control). For each condition, three biological repeats were sampled. Total RNA isolation was performed as previously described [<xref rid="pone.0155139.ref020" ref-type="bibr">20</xref>]. Subsequently, rRNA was depleted using the Ribo-Zero rRNA Removal Kit (Illumina) as per manufacturer&#x02019;s instructions. RNA integrity was analyzed using Experion RNA StdSens Chips (Bio-Rad). RNA quantity and purity was assessed using a NanoDrop ND-1000 spectrophotometer. Samples were sent to the Genomics Core Facility of EMBL (Heidelberg, Germany) for library construction and RNA sequencing using the Illumina HiSeq 2000 platform. The RNA sequencing data sets reported in this article are available in the ArrayExpress database (ArrayExpress accession: E-MTAB-4691; <ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/arrayexpress">http://www.ebi.ac.uk/arrayexpress</ext-link>).</p><p>For data analysis, FastQC was used to verify the quality of the raw sequencing reads [<xref rid="pone.0155139.ref024" ref-type="bibr">24</xref>]. Next, sequences were aligned to the reference <italic>P</italic>. <italic>aeruginosa</italic> UCBPP-PA14 genome (NC_008463.1) with Bowtie2 using standard settings. Only samples in which more than 90% of the reads aligned exactly once were withheld for further analysis (see <xref ref-type="supplementary-material" rid="pone.0155139.s003">S2 Table</xref>). Subsequently, read counts per gene were calculated for each sample with Htseq-count [<xref rid="pone.0155139.ref025" ref-type="bibr">25</xref>]. The DESeq2 package [<xref rid="pone.0155139.ref026" ref-type="bibr">26</xref>] was used to normalize the data and to detect differential expression between treated and control samples using a False Discovery Rate (FDR) &#x0003c; 0.05. Next, a network analysis was carried out using PheNetic [<xref rid="pone.0155139.ref027" ref-type="bibr">27</xref>]. This analysis looks for both regulatory programs common to multiple differentially expressed genes and for downstream processes which are activated by differentially expressed genes, thus visualizing important molecular processes underlying the observed phenotype of the tested organism. Input data consist of three types of information: an interaction network of the tested organism, the differential expression data of all genes in the network and a gene list of significantly differentially expressed genes. Currently, no interaction network exists for <italic>P</italic>. <italic>aeruginosa</italic> PA14. For this reason, an interaction network for <italic>P</italic>. <italic>aeruginosa</italic> PAO1 was created, using different publicly available datasets (STRING [<xref rid="pone.0155139.ref028" ref-type="bibr">28</xref>], KEGG [<xref rid="pone.0155139.ref029" ref-type="bibr">29</xref>,<xref rid="pone.0155139.ref030" ref-type="bibr">30</xref>]). Subsequently, the genes of PA14 were mapped to the genes of PAO1 using the Rapid Annotation using Subsystem Technology (RAST) server [<xref rid="pone.0155139.ref031" ref-type="bibr">31</xref>]. Significantly differentially expressed genes were defined as the 100 genes having the highest log2-fold change. PheNetic was run using the standard parameters on the web server (22). Gene Ontology (GO) enrichment was performed on the resulting subnetwork using the Cytoscape [<xref rid="pone.0155139.ref032" ref-type="bibr">32</xref>] plugin BiNGO [<xref rid="pone.0155139.ref033" ref-type="bibr">33</xref>] (hypergeometric test, &#x003b1; &#x0003c; 0.05, FDR correction). GO annotations for <italic>P</italic>. <italic>aeruginosa</italic> PAO1 were retrieved from Uniprot [<xref rid="pone.0155139.ref034" ref-type="bibr">34</xref>].</p></sec><sec id="sec013"><title>Screening of a transposon mutant library</title><p>A <italic>P</italic>. <italic>aeruginosa</italic> PA14 transposon library [<xref rid="pone.0155139.ref035" ref-type="bibr">35</xref>] was screened for increased sensitivity or resistance to SPI031. Mutants were allowed to grow in 1/20 TSB in 96-well plates. After overnight incubation, the cultures were diluted 100-fold in 1/20 TSB containing either 0.2x MIC or 2x MIC of SPI031 (see <xref ref-type="supplementary-material" rid="pone.0155139.s002">S1 Table</xref>) to detect hypersensitive or resistant mutants, respectively. Next, the plates were incubated while shaking for 24 h at 37&#x000b0;C. Growth was monitored by measuring the OD<sub>595</sub>. Mutants were identified as hypersensitive if their OD<sub>595</sub> was less than 0.05 after incubation in the presence of 0.2x MIC of SPI031. On the other hand, mutants were identified as resistant if their OD<sub>595</sub> was more than 0.1 after incubation in the presence of 2x MIC of SPI031. Subsequently, the susceptibility of the selected mutants was validated by detailed monitoring of growth in the presence of either 0.2x or 2x MIC of SPI031 using an automated OD plate reader (Bioscreen C, Oy Growth curves Ab Ltd).</p></sec><sec id="sec014"><title>Statistical analysis</title><p>All experiments were repeated independently at least 3 times. Statistical significance of data was determined by applying a student&#x02019;s t-test using GraphPad Prism version 5 (GraphPad Software, USA). Differences were considered significant if *p &#x02264; 0.05.</p></sec></sec><sec sec-type="results" id="sec015"><title>Results</title><sec id="sec016"><title>SPI031 displays rapid killing activity against pathogenic bacteria</title><p>Recently, we demonstrated that SPI031 exhibits antibacterial effects against different bacterial pathogens (MIC between 4.63 and 18.5 &#x003bc;g/ml) [<xref rid="pone.0155139.ref015" ref-type="bibr">15</xref>]. In the present study, time-kill assays were performed to analyze the killing rate of SPI031 and to compare it with that of conventional antibiotics frequently used in clinical settings. MIC values for SPI031 and selected antibiotics were determined and are listed in <xref ref-type="supplementary-material" rid="pone.0155139.s002">S1 Table</xref>. <xref ref-type="fig" rid="pone.0155139.g002">Fig 2A</xref> shows the killing curves of SPI031 and vancomycin for <italic>S</italic>. <italic>aureus</italic>. At 1x MIC of SPI031, the bactericidal endpoint was achieved after 24 h, with a reduction of CFU by almost 6 log units. Vancomycin had a low bactericidal activity at 1x MIC and substantial regrowth was observed after 2 h. At 4x MIC of SPI031, more than 99% of the bacteria were killed within 30 min. In comparison, the killing activity of vancomycin at 4x MIC was much slower, with a reduction of the initial inoculum by only 2 log units within 24 h.</p><p>The killing kinetics of SPI031 and polymyxin B against <italic>P</italic>. <italic>aeruginosa</italic> are shown in <xref ref-type="fig" rid="pone.0155139.g002">Fig 2B</xref>. At 1x MIC of SPI031, a 4-log reduction of viable counts was achieved and regrowth was observed after 24 h. At 1x MIC of polymyxin B, a 5-log reduction of the bacterial inoculum was obtained within 10 min, but fast regrowth was observed after 30 min. At 4x MIC, the bactericidal activity of both SPI031 and polymyxin B was very fast (7-log reduction within 30 min), indicating that at higher therapeutic concentrations, SPI031 and polymyxin B display similar killing activities.</p><fig id="pone.0155139.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0155139.g002</object-id><label>Fig 2</label><caption><title>Time-kill kinetics of SPI031 against <italic>S</italic>. <italic>aureus</italic> and <italic>P</italic>. <italic>aeruginosa</italic>.</title><p>(A) Concentration-dependent killing of <italic>S</italic>. <italic>aureus</italic> by SPI031 and vancomycin (VAN). (B) Concentration-dependent killing of <italic>P</italic>. <italic>aeruginosa</italic> by SPI031 and polymyxin B (PMB). All data represent means &#x000b1; standard error of the mean (SEM) from 3 independent experiments (*p &#x0003c; 0.05; **p &#x0003c; 0.01; ***p &#x0003c; 0.001). The black dotted lines indicate the lower limit of detection.</p></caption><graphic xlink:href="pone.0155139.g002"/></fig></sec><sec id="sec017"><title>Frequency of resistance development against SPI031 is low</title><p>To investigate the potency of spontaneous resistance development against SPI031, the frequency by which <italic>P</italic>. <italic>aeruginosa</italic> mutants resistant to SPI031 emerge was determined, and compared to those associated with conventional antibiotics. The mutation frequency of <italic>P</italic>. <italic>aeruginosa</italic> for SPI031 (6.09 &#x000b1; 2.10 x 10<sup>&#x02212;8</sup>) was significantly lower than for polymyxin B (2.20 &#x000b1; 0.44 x 10<sup>&#x02212;7</sup>) and not significantly different than that for ofloxacin (4.03 &#x000b1; 1.10 x 10<sup>&#x02212;8</sup>). Interestingly, no spontaneous SPI031-resistant mutants of <italic>S</italic>. <italic>aureus</italic> could be generated (limit of detection &#x0003c; 10<sup>&#x02212;9</sup>).</p></sec><sec id="sec018"><title>SPI031 exhibits non-specific inhibition of macromolecular biosynthesis pathways</title><p>To investigate the effect of SPI031 on macromolecular pathways, a macromolecular synthesis assay was performed. The percentage of incorporation of radiolabeled precursors into macromolecules was determined upon exposure to SPI031 and was compared with results obtained after treatment with known inhibitors of DNA, RNA or protein synthesis: ciprofloxacin, rifampicin and tetracycline, respectively (<xref ref-type="fig" rid="pone.0155139.g003">Fig 3</xref>). At 4x MIC of SPI031, no preferential inhibition of tested macromolecular processes was observed, a profile that is observed for antibacterial agents that act by disrupting the integrity of the cytoplasmic membrane [<xref rid="pone.0155139.ref036" ref-type="bibr">36</xref>&#x02013;<xref rid="pone.0155139.ref039" ref-type="bibr">39</xref>].</p><fig id="pone.0155139.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0155139.g003</object-id><label>Fig 3</label><caption><title>Effect of SPI031 on macromolecular synthesis in <italic>S</italic>. <italic>aureus</italic>.</title><p>Incorporation of [methyl-<sup>3</sup>H]thymidine (A), [5,6-<sup>3</sup>H]uridine (B) and L-[G-<sup>3</sup>H]glutamine (C) by <italic>S</italic>. <italic>aureus</italic> after treatment with SPI031, ciprofloxacin, rifampicin or tetracycline at 4x MIC. Incorporation was expressed as percentage of untreated control. Values shown are means &#x000b1; SD of triplicate determinations.</p></caption><graphic xlink:href="pone.0155139.g003"/></fig></sec><sec id="sec019"><title>SPI031 permeabilizes the membrane(s) of both <italic>S</italic>. <italic>aureus</italic> and <italic>P</italic>. <italic>aeruginosa</italic></title><p>Based on the results of the macromolecular synthesis analysis, we further investigated membrane permeabilisation. Permeabilization of the membrane of <italic>S</italic>. <italic>aureus</italic> after treatment with SPI031 was assessed using the nucleic acid stain SYTOX green. This stain only enters the cytoplasm if the membrane is compromised. Upon uptake, SYTOX green binds to nucleic acids, which in turn results in increased fluorescence [<xref rid="pone.0155139.ref040" ref-type="bibr">40</xref>]. Addition of SPI031 to <italic>S</italic>. <italic>aureus</italic> cells caused a concentration-dependent increase in SYTOX green fluorescence, indicating that SPI031 permeabilizes the membrane (<xref ref-type="fig" rid="pone.0155139.g004">Fig 4A</xref>). At 1x MIC of SPI031, membrane permeabilization was comparable to that after treatment with the toxin melittin from bee-venom, which was used as a positive control. Inner membrane permeability of <italic>P</italic>. <italic>aeruginosa</italic> after treatment with SPI031 was also investigated using SYTOX green (<xref ref-type="fig" rid="pone.0155139.g004">Fig 4B</xref>). SPI031 was able to rapidly induce SYTOX green uptake, suggesting that the compound also permeabilizes the inner membrane of <italic>P</italic>. <italic>aeruginosa</italic>.</p><p>Next, permeabilization of the outer membrane of <italic>P</italic>. <italic>aeruginosa</italic> was determined after treatment with different concentrations of SPI031, using the hydrophobic probe NPN. This probe is normally excluded from bacterial membranes due to the presence of lipopolysaccharide molecules on the outer membrane [<xref rid="pone.0155139.ref041" ref-type="bibr">41</xref>]. However, when the outer membrane is permeabilized, NPN can enter the membranes, leading to a strong increase in fluorescence [<xref rid="pone.0155139.ref042" ref-type="bibr">42</xref>]. As shown in <xref ref-type="fig" rid="pone.0155139.g004">Fig 4C</xref>, SPI031 rapidly permeabilized the outer membrane of <italic>P</italic>. <italic>aeruginosa</italic> in a concentration-dependent manner. At 1x MIC of SPI031, the NPN uptake was similar to that of the positive control polymyxin B.</p><fig id="pone.0155139.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0155139.g004</object-id><label>Fig 4</label><caption><title>Effect of SPI031 on membrane permeability.</title><p>(A) Effect of increasing concentrations of SPI031 on the membrane permeability of <italic>S</italic>. <italic>aureus</italic>, monitored by the uptake of SYTOX green. Cells treated with melittin (MEL) (1x MIC) served as a positive control. (B) Inner membrane permeabilization of <italic>P</italic>. <italic>aeruginosa</italic> after treatment with different concentrations of SPI031, determined by measuring SYTOX green uptake. Melittin (MEL) (1x MIC) was used as a positive control. (C) Outer membrane permeabilization of <italic>P</italic>. <italic>aeruginosa</italic> after treatment with different concentrations of SPI031, assessed by quantifying NPN uptake. Cells treated with polymyxin B (PMB) (1x MIC) were used as a positive control. Data represent the means of three independent replicates &#x000b1; SEM (*p &#x0003c; 0.05; **p &#x0003c; 0.01; ***p &#x0003c; 0.001 compared to untreated control).</p></caption><graphic xlink:href="pone.0155139.g004"/></fig></sec><sec id="sec020"><title>SPI031 targets the phospholipid component of bacterial membranes</title><p>In addition to lipids, the bacterial membrane contains many other biological molecules. To investigate the direct interaction of SPI031 with the phospholipid bilayer, a carboxyfluorescein (CF) leakage assay was performed. For this assay, CF-loaded liposomes were used that mimic the composition of the phospholipid bilayer of <italic>S</italic>. <italic>aureus</italic>. As shown in <xref ref-type="fig" rid="pone.0155139.g005">Fig 5</xref>, SPI031 caused substantial release of CF at 4x MIC, and an intermediate release at 1x MIC. These results indicate that SPI031 is able to interact with the phospholipid bilayer, which in turn results in destabilization of the cytoplasmic membrane.</p><fig id="pone.0155139.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0155139.g005</object-id><label>Fig 5</label><caption><title>Integrity of <italic>S</italic>. <italic>aureus</italic> liposomes after treatment with SPI031 at 1x MIC and 4x MIC.</title><p>SDS (5%) and tetracycline (TET) (4x MIC) were used as positive and negative controls, respectively. Means and standard deviation (SD) of 3 independent experiments are shown (*p &#x0003c; 0.05; **p &#x0003c; 0.01; ***p &#x0003c; 0.001 compared to treatment with tetracycline).</p></caption><graphic xlink:href="pone.0155139.g005"/></fig></sec><sec id="sec021"><title>Membrane damage caused by SPI031 can be visualized microscopically</title><p>To further investigate the effect of SPI031 on the membrane, the membrane stain FM 4&#x02013;64 was used (<xref ref-type="fig" rid="pone.0155139.g006">Fig 6</xref>). Treatment of exponentially growing cells of <italic>S</italic>. <italic>aureus</italic> and <italic>P</italic>. <italic>aeruginosa</italic> with solvent control DMSO resulted in uniformly stained membranes. In contrast, treatment of the cells with SPI031 at 1x MIC resulted in specific membrane accumulations. Heterogeneity in membrane staining was also seen in <italic>P</italic>. <italic>aerugino</italic>sa cells treated with 1x MIC of polymyxin B. In contrast, <italic>P</italic>. <italic>aeruginosa</italic> cells exposed to 1x MIC of tobramycin showed no membrane defects (data not shown). Overall, these results further corroborate a clear direct effect of SPI031 on the bacterial membrane.</p><fig id="pone.0155139.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0155139.g006</object-id><label>Fig 6</label><caption><title>Microscopic analysis of the cell membrane after treatment with SPI031.</title><p>Fluorescent images of <italic>S</italic>. <italic>aureus</italic> cells (upper row) and <italic>P</italic>. <italic>aeruginosa</italic> cells (lower row) stained with FM 4&#x02013;64 in the absence or presence of 1x MIC of SPI031. Scale bar corresponds to 2 &#x003bc;m. Images were processed with unsharp mask of Zen 2.0.</p></caption><graphic xlink:href="pone.0155139.g006"/></fig></sec><sec id="sec022"><title>Whole genome sequencing of SPI031-resistant mutants reveals mutations in genes coding for proteins involved in outer membrane synthesis and efflux mechanisms</title><p>Mutational analysis of spontaneous resistant mutants is an approach commonly used to gain more information about primary targets of new antibacterial compounds [<xref rid="pone.0155139.ref043" ref-type="bibr">43</xref>&#x02013;<xref rid="pone.0155139.ref046" ref-type="bibr">46</xref>]. Therefore, three independent spontaneous SPI031-resistant mutants of <italic>P</italic>. <italic>aeruginosa</italic> were selected and were subjected to whole genome sequencing. All identified mutations are listed in <xref ref-type="supplementary-material" rid="pone.0155139.s004">S3 Table</xref>. One mutant carried mutations in <italic>nfxB</italic>, which codes for the repressor of the MexCD-OprJ multidrug efflux pump [<xref rid="pone.0155139.ref047" ref-type="bibr">47</xref>]. These findings indicate that SPI031 may be a substrate for this efflux pump. The two other mutants had mutations in genes coding for proteins involved in outer membrane synthesis (<italic>htrB</italic> and PA14_23400) [<xref rid="pone.0155139.ref048" ref-type="bibr">48</xref>,<xref rid="pone.0155139.ref049" ref-type="bibr">49</xref>]. For these mutants, we hypothesize that a change in the structure of the outer membrane is responsible for the observed resistance. In addition, two <italic>P</italic>. <italic>aeruginosa</italic> mutants acquired mutations in intergenic regions.</p></sec><sec id="sec023"><title>Transcriptome analysis of bacteria challenged with SPI031 reveals altered expression of genes involved in fatty acid biosynthesis and lipid metabolic processes</title><p>A transcriptome analysis was performed using RNA sequencing to uncover the cellular responses to SPI031. To assess the direct effects of the compound on cellular processes, the transcription profile was determined from cells treated for 5 min with a sub-inhibitory concentration of SPI031. 304 genes were differentially expressed upon treatment with SPI031. Subsequently, a network analysis was conducted using PheNetic (<xref ref-type="fig" rid="pone.0155139.g007">Fig 7</xref>). To investigate the regulatory pathways altered by SPI031, a GO enrichment analysis was performed on the resulting subnetwork (see <xref ref-type="supplementary-material" rid="pone.0155139.s005">S4 Table</xref>). This analysis demonstrated that SPI031 alters expression of genes involved in fatty acid biosynthesis and lipid metabolic processes, indicating that SPI031 induces membrane damage. In addition, SPI031 also affects expression of genes involved in alginic acid metabolism, peroxidase activity, cobalamine and tetrapyrrole metabolism, translation and proline biosynthesis and metabolism, which are believed to be secondary effects.</p><fig id="pone.0155139.g007" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0155139.g007</object-id><label>Fig 7</label><caption><title>Network analysis of differential expression data.</title><p>Resulting subnetwork from network analysis of RNAseq data using PheNetic [<xref rid="pone.0155139.ref027" ref-type="bibr">27</xref>]. This subnetwork shows molecular mechanisms which are differentially active when comparing <italic>P</italic>. <italic>aeruginosa</italic> cells treated with 0.2x MIC of SPI031 to <italic>P</italic>. <italic>aeruginosa</italic> cells treated with DMSO. Nodes and connecting lines represent genes and interactions between these genes, respectively. Red dots represent genes overexpressed in the SPI031-treated organisms with respect to the DMSO-treated organism and vice versa for green dots. The color of the connecting lines represents the type of interaction in between genes. Yellow lines represent metabolic interactions, red lines represent regulatory interactions and green lines represent protein-protein interactions.</p></caption><graphic xlink:href="pone.0155139.g007"/></fig></sec><sec id="sec024"><title>Mutants with aberrant cell division show increased sensitivity to SPI031</title><p>To uncover tolerance mechanisms of <italic>P</italic>. <italic>aeruginosa</italic> against SPI031 and to obtain more insight into its mode of action, a library of transposon insertion mutants of <italic>P</italic>. <italic>aeruginosa</italic> [<xref rid="pone.0155139.ref035" ref-type="bibr">35</xref>] was screened to identify genes associated with altered sensitivity to the compound. This led to the recovery of two SPI031-hypersensitive mutants affected in <italic>minC</italic> and <italic>minD</italic>, which are genes encoding proteins that are involved in cell division (see <xref ref-type="supplementary-material" rid="pone.0155139.s001">S1 Fig</xref>). More specifically, MinC and MinD act in concert to form a nonspecific inhibitor of septation [<xref rid="pone.0155139.ref050" ref-type="bibr">50</xref>]. Hypersensitivity to SPI031 of an <italic>E</italic>. <italic>coli minC</italic> deletion mutant [<xref rid="pone.0155139.ref051" ref-type="bibr">51</xref>] could also be demonstrated (data not shown). These results suggest that an aberrant cell division results in increased sensitivity to the antibacterial activity of SPI031.</p></sec></sec><sec sec-type="conclusions" id="sec025"><title>Discussion</title><p>Recently, we identified the promising antibacterial compound SPI031, which possesses antibacterial activity against various Gram-positive and Gram-negative pathogens, including the clinically important pathogens <italic>S</italic>. <italic>aureus</italic> and <italic>P</italic>. <italic>aeruginosa</italic> [<xref rid="pone.0155139.ref015" ref-type="bibr">15</xref>]. Moreover, additional tests demonstrated antibacterial activity against a representative selection of ESKAPE pathogens (see <xref ref-type="supplementary-material" rid="pone.0155139.s006">S5 Table</xref>). Furthermore, we demonstrated that SPI031-functionalised titanium surfaces show significant antibacterial activity both <italic>in vitro</italic> and <italic>in vivo</italic> [<xref rid="pone.0155139.ref017" ref-type="bibr">17</xref>].</p><p>In the present study, time-kill kinetic studies were performed to assess the bactericidal activity of SPI031 against <italic>S</italic>. <italic>aureus</italic> and <italic>P</italic>. <italic>aeruginosa</italic>. Interestingly, SPI031 displayed superior bactericidal activity against <italic>S</italic>. <italic>aureus</italic> compared to vancomycin, an antibiotic frequently used to treat staphylococcal infections [<xref rid="pone.0155139.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0155139.ref007" ref-type="bibr">7</xref>]. It should be noted that time-kill assays were performed with late exponential phase populations of <italic>S</italic>. <italic>aureus</italic>, which could explain the observed low activity of vancomycin [<xref rid="pone.0155139.ref052" ref-type="bibr">52</xref>,<xref rid="pone.0155139.ref053" ref-type="bibr">53</xref>]. When comparing the killing kinetics of SPI031 and last-resort antibiotic polymyxin B for <italic>P</italic>. <italic>aeruginosa</italic>, regrowth was observed for both antibacterial agents at 1x MIC, although this occurred at a much slower rate for SPI031. The fast regrowth observed after treatment with low concentrations of polymyxin B could be explained by selective amplification of less-susceptible sub-populations [<xref rid="pone.0155139.ref054" ref-type="bibr">54</xref>] and is in accordance with previous studies examining the time-kill kinetics of polymyxins [<xref rid="pone.0155139.ref055" ref-type="bibr">55</xref>,<xref rid="pone.0155139.ref056" ref-type="bibr">56</xref>]. At higher concentrations, both antibiotics rapidly displayed bactericidal activities against <italic>P</italic>. <italic>aeruginosa</italic>, which is a desirable feature in the fight against recalcitrant infections. In follow-up studies, it will be investigated whether these <italic>in vitro</italic> time-kill data are predictive of <italic>in vivo</italic> efficacy.</p><p>In order to be effective in treatment, it is important that the incidence of resistance to SPI031 is low. For this reason we determined the frequency by which <italic>P</italic>. <italic>aeruginosa</italic> mutants resistant to SPI031 emerge. The results were compared to those of conventional antibiotics. The mutation frequency of <italic>P</italic>. <italic>aeruginosa</italic> for SPI031 and ofloxacin was lower compared with polymyxin B. In addition, no spontaneous SPI031-resistant mutants of <italic>S</italic>. <italic>aureus</italic> could be recovered. These results highlight the potential advantage of using SPI031 in the treatment of infections.</p><p>To gain more insight into the mode of action of SPI031, we monitored the ability of the compound to inhibit bacterial macromolecular synthesis processes. No specific inhibition of DNA, RNA, or protein synthesis could be observed. These results are reminiscent of those obtained after treatment of bacterial cells with membrane damaging agents that cause leakage of cytoplasmic components [<xref rid="pone.0155139.ref036" ref-type="bibr">36</xref>&#x02013;<xref rid="pone.0155139.ref039" ref-type="bibr">39</xref>], suggesting that SPI031 has membrane damaging activity. It is also known that membrane damaging agents have a rapid bactericidal activity and a low potential for the development of resistant mutants [<xref rid="pone.0155139.ref057" ref-type="bibr">57</xref>], which is consistent with the results discussed above.</p><p>To further investigate the effect of SPI031 on the cell membrane, permeability assays were performed. SPI031 was able to disrupt the membrane of <italic>S</italic>. <italic>aureus</italic>, facilitating the intracellular uptake of SYTOX green, in a dose-dependent manner. SPI031 also permeabilized the inner and outer membrane of <italic>P</italic>. <italic>aeruginosa</italic>, as evidenced by the uptake of the fluorescent probes SYTOX green and NPN, respectively. Furthermore, SPI031 was able to induce CF leakage from liposomes, suggesting that the compound causes membrane permeabilization through direct physical interaction with the phospholipid bilayer. Also, by using the fluorescent membrane dye FM4-64, it was shown that <italic>S</italic>. <italic>aureus</italic> and <italic>P</italic>. <italic>aeruginosa</italic> cells treated with SPI031 have distinct membrane accumulations, which is in corroboration with the results obtained in the biophysical studies mentioned above.</p><p>Whole genome sequencing of spontaneous SPI031-resistant mutants of <italic>P</italic>. <italic>aeruginosa</italic> revealed mutations in <italic>nfxB</italic>, which codes for the repressor of the MexCD-OprJ multidrug efflux pump. These mutations probably cause a loss of function of NfxB, which leads to up-regulation of <italic>mexCD-oprJ</italic> and increased resistance [<xref rid="pone.0155139.ref058" ref-type="bibr">58</xref>]. These results confirm our previous observations regarding the role of the <italic>mex</italic> efflux pumps in intrinsic resistance of <italic>P</italic>. <italic>aeruginosa</italic> for SPI031 [<xref rid="pone.0155139.ref015" ref-type="bibr">15</xref>]. These findings are not unexpected given that practically all classes of antibiotics are known to be substrates of multidrug efflux pumps [<xref rid="pone.0155139.ref059" ref-type="bibr">59</xref>]. In addition, mutations were found in <italic>htrB</italic> and PA14_23400, two genes that are involved in outer membrane synthesis. HrtB is an acyltransferase involved in lipid A biosynthesis and PA14_23400 presumably plays a role in O-antigen biosynthesis [<xref rid="pone.0155139.ref048" ref-type="bibr">48</xref>,<xref rid="pone.0155139.ref049" ref-type="bibr">49</xref>]. We assume that these mutations confer alterations in outer membrane composition, thereby leading to increased resistance. Hence these results may indicate a direct effect of SPI031 on the outer membrane, as was observed experimentally.</p><p>Transcriptome analysis demonstrated that the expression of genes involved in the fatty acid biosynthesis and lipid metabolic processes was already altered after 5 min of treatment with SPI031. We hypothesize that the cell tries to compensate for the membrane defects induced by SPI031, which supports the results obtained above. In addition, SPI031 also affects the expression of genes involved in alginic acid metabolism. Alginate is an exopolysaccharide that plays a central role in the formation of biofilms [<xref rid="pone.0155139.ref060" ref-type="bibr">60</xref>]. Thus, these results may suggest that SPI031 inhibits biofilm formation by interfering with alginate production. This is in line with our previous observations which showed that SPI031 exhibits antibiofilm properties [<xref rid="pone.0155139.ref015" ref-type="bibr">15</xref>]. Furthermore, the analysis showed an enrichment of genes related to peroxidase activity, which is a component of the oxidative stress response. Interestingly, SPI031 also interferes with the transcription of genes that are required for cobalamine and tetrapyrrole metabolism. To our knowledge, these metabolisms have never been linked before to the mode of action of an antibiotic agent. Thus, further research is needed to clarify these findings.</p><p>Finally, we found that <italic>minC</italic> and <italic>minD</italic> transposon mutants displaying aberrant cell division are hypersensitive to SPI031. These results suggest that cell division contributes to tolerance mechanisms against SPI031 and are in agreement with a previous study, showing that a mutant lacking a gene that regulates septum formation is more susceptible to a membrane-targeting antibiotic [<xref rid="pone.0155139.ref061" ref-type="bibr">61</xref>]. At this stage, it is not clear how exactly aberrant cell division leads to increased susceptibility to SPI031. Changes in the divisome might induce destabilization of the membrane(s), facilitating the direct interaction of SPI031 with the membrane. The role of cell division in tolerance mechanisms against SPI031 will be studied further in the near future. As antibiotic-resistant bacteria are spreading at an alarming rate, the development of alternative treatment options becomes crucial. One of these approaches involves the identification of compounds that potentiate the activity of an antibiotic, thereby lowering the risk for development of resistance [<xref rid="pone.0155139.ref062" ref-type="bibr">62</xref>]. Hence, in future experiments, it could be interesting to assess whether inhibitors of cell division potentiate the activity of SPI031.</p><p>Per mode of action, SPI031 could potentially be used in antibacterial treatments. However, when tested against human keratinocytes and human hepatoma cells, a reduction in cell viability was observed even at low concentrations (data not shown). Toxicity is often a major obstacle in therapeutic application of membrane-damaging antibacterial agents. The design of structural analogs of SPI031 with higher specificity towards the bacterial membranes and minimal toxicity towards eukaryotic membranes may provide a solution to this problem. Indeed, previous work has shown that the evaluation of structural analogs of antibacterial molecules represents a good strategy to improve antibacterial potency and to minimize toxicity [<xref rid="pone.0155139.ref063" ref-type="bibr">63</xref>&#x02013;<xref rid="pone.0155139.ref065" ref-type="bibr">65</xref>]. Of note, various carbazoles have been reported that exhibit low cellular toxicity at clinically relevant concentrations, pointing to the possibility to further develop SPI031 into a new agent for the treatment of topical bacterial infections [<xref rid="pone.0155139.ref016" ref-type="bibr">16</xref>]. Furthermore, we previously demonstrated that SPI031 is a suitable candidate for the development of new anti-infective coatings on implants [<xref rid="pone.0155139.ref017" ref-type="bibr">17</xref>]. In that study, we developed titanium substrates on which SPI031 was covalently linked. We found that immobilized SPI031 remains active under both <italic>in vivo</italic> and <italic>in vivo</italic> conditions. In addition, we demonstrated that immobilized SPI031 displays no cytotoxic effects on osteogenic and vasculogenic human cells important for osseointegration and bone repair.</p><p>In summary, we have shown that SPI031 displays rapid bactericidal activity and a low tendency for the development of resistance. In addition, we have demonstrated that the membrane is the primary target of SPI031. In recent years it has become clear that membrane-targeting agents are excellent candidates for the treatment of persistent infections caused by biofilm-forming bacteria [<xref rid="pone.0155139.ref057" ref-type="bibr">57</xref>]. Taken all these factors into account, we believe that SPI031 has the potential to serve a as backbone molecule for the development of new anti-infective therapies, such as coatings for implants. Further investigations such as physicochemical studies, toxicity tests, animal efficacy and pharmacokinetic/pharmacodynamic studies will be needed to fully reveal the therapeutic potential of this class of molecules.</p></sec><sec sec-type="supplementary-material" id="sec026"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0155139.s001"><label>S1 Fig</label><caption><title>Hypersensitivity of <italic>P</italic>. <italic>aeruginosa minC</italic> and <italic>minD</italic> mutants to SPI031.</title><p>Growth curves of WT, <italic>minC</italic> mutant and <italic>minD</italic> mutant in the absence and presence of 0.2x MIC of SPI031. OD<sub>595</sub> was measured every 10 min using an automated OD plate reader. The experiment was repeated three times and one representative repeat is shown.</p><p>(TIF)</p></caption><media xlink:href="pone.0155139.s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155139.s002"><label>S1 Table</label><caption><title>MIC values of SPI031 and other antibiotics against <italic>S</italic>. <italic>aureus</italic> and <italic>P</italic>. <italic>aeruginosa</italic>.</title><p>(DOC)</p></caption><media xlink:href="pone.0155139.s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155139.s003"><label>S2 Table</label><caption><title>Bowtie2 alignment statistics for samples treated with DMSO (solvent control) and 0.2x MIC of SPI031.</title><p>(DOC)</p></caption><media xlink:href="pone.0155139.s003.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155139.s004"><label>S3 Table</label><caption><title>Mutations identified in spontaneous SPI031-resistant mutants<sup>1</sup>.</title><p><sup>1</sup>Abbreviations: SRM, spontaneous resistant mutant; SNV, single nucleotide variant; Del, deletion; In, insertion.</p><p>(DOC)</p></caption><media xlink:href="pone.0155139.s004.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155139.s005"><label>S4 Table</label><caption><title>GO enrichment analysis of differentially expressed genes.</title><p>(XLS)</p></caption><media xlink:href="pone.0155139.s005.xls"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155139.s006"><label>S5 Table</label><caption><title>MIC values of SPI031 against ESKAPE pathogens.</title><p>(DOCX)</p></caption><media xlink:href="pone.0155139.s006.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors declare no conflict of interest. We would like to thank Petra Windmolders (Lab of Hepatology, KU Leuven) for her technical assistance.</p></ack><ref-list><title>References</title><ref id="pone.0155139.ref001"><label>1</label><mixed-citation publication-type="book"><collab>World Health Organization</collab>. <chapter-title>Antimicrobial resistance: global report on surveillance</chapter-title><publisher-name>WHO</publisher-name>, <publisher-loc>Geneva</publisher-loc>; <year>2014</year>.</mixed-citation></ref><ref id="pone.0155139.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Lowy</surname><given-names>FD</given-names></name>. <article-title><italic>Staphylococcus aureus</italic> infections</article-title>. <source>N Engl J Med</source>. <year>1998</year>;<volume>8</volume>: <fpage>520</fpage>&#x02013;<lpage>532</lpage>.<pub-id pub-id-type="pmid">9709046</pub-id></mixed-citation></ref><ref id="pone.0155139.ref003"><label>3</label><mixed-citation publication-type="book"><collab>European Centre for Disease Prevention and Control</collab>. <chapter-title>Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals</chapter-title>
<publisher-name>ECDC</publisher-name>, <publisher-loc>Stockholm</publisher-loc>; <year>2013</year>.</mixed-citation></ref><ref id="pone.0155139.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Campoccia</surname><given-names>D</given-names></name>, <name><surname>Montanaro</surname><given-names>L</given-names></name>, <name><surname>Ariola</surname><given-names>CR</given-names></name>. <article-title>The significance of infection related to orthopedic devices and issues of antibiotic resistance</article-title>. <source>Biomaterials</source>. <year>2006</year>;<volume>27</volume>: <fpage>2331</fpage>&#x02013;<lpage>2339</lpage>. <?supplied-pmid 16364434?><pub-id pub-id-type="pmid">16364434</pub-id></mixed-citation></ref><ref id="pone.0155139.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Moellering</surname><given-names>RC</given-names><suffix>Jr</suffix></name>. <article-title>The growing menace of community-acquired methicillin-resistant <italic>Staphylococcus aureus</italic></article-title>. <source>Ann Intern Med</source>. <year>2015</year>;<volume>144</volume>: <fpage>368</fpage>&#x02013;<lpage>370</lpage>.<pub-id pub-id-type="pmid">16520479</pub-id></mixed-citation></ref><ref id="pone.0155139.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Deresinski</surname><given-names>S</given-names></name>. <article-title>Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant <italic>Staphylococcus aureus</italic> infections</article-title>. <source>Clin Infect Dis</source>. <year>2009</year>;<volume>49</volume>: <fpage>1072</fpage>&#x02013;<lpage>1079</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/605572">10.1086/605572</ext-link></comment>
<?supplied-pmid 19725789?><pub-id pub-id-type="pmid">19725789</pub-id></mixed-citation></ref><ref id="pone.0155139.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>C</given-names></name>, <name><surname>Bayer</surname><given-names>A</given-names></name>, <name><surname>Cosgrove</surname><given-names>SE</given-names></name>, <name><surname>Daum</surname><given-names>RS</given-names></name>, <name><surname>Fridkin</surname><given-names>SK</given-names></name>, <name><surname>Gorwitz</surname><given-names>RJ</given-names></name>, <etal>et al</etal>
<article-title>Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant <italic>Staphylococcus aureus</italic> infections in adults and children</article-title>. <source>Clin Infect Dis</source>. <year>2011</year>;<volume>52</volume>: <fpage>e18</fpage>&#x02013;<lpage>55</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/cid/ciq146">10.1093/cid/ciq146</ext-link></comment>
<?supplied-pmid 21208910?><pub-id pub-id-type="pmid">21208910</pub-id></mixed-citation></ref><ref id="pone.0155139.ref008"><label>8</label><mixed-citation publication-type="journal"><collab>Centers for Disease Control and Prevention</collab>. <article-title><italic>Staphylococcus aureus</italic> resistant to vancomycin&#x02014;United States</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2002</year>;<volume>51</volume>: <fpage>565</fpage>&#x02013;<lpage>567</lpage>. <?supplied-pmid 12139181?><pub-id pub-id-type="pmid">12139181</pub-id></mixed-citation></ref><ref id="pone.0155139.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Palazzo</surname><given-names>ICV</given-names></name>, <name><surname>Araujo</surname><given-names>MLC</given-names></name>, <name><surname>Darini</surname><given-names>ALC</given-names></name>. <article-title>First report of vancomycin-resistant staphylococci isolated from healthy carriers in Brazil</article-title>. <source>J Clin Microbiol</source>. <year>2005</year>;<volume>43</volume>: <fpage>179</fpage>&#x02013;<lpage>185</lpage>. <?supplied-pmid 15634969?><pub-id pub-id-type="pmid">15634969</pub-id></mixed-citation></ref><ref id="pone.0155139.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Bataineh</surname><given-names>HA</given-names></name>. <article-title>Resistance of <italic>Staphylococcus aureus</italic> to vancomycin in Zarqa, Jordan</article-title>. <source>Pak J Med Sci</source>. <year>2006</year>;<volume>22</volume>: <fpage>144</fpage>&#x02013;<lpage>148</lpage>.</mixed-citation></ref><ref id="pone.0155139.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Driscoll</surname><given-names>JA</given-names></name>, <name><surname>Brody</surname><given-names>SL</given-names></name>, <name><surname>Kollef</surname><given-names>MH</given-names></name>. <article-title>The epidemiology, pathogenesis and treatment of <italic>Pseudomonas aeruginosa</italic> infections</article-title>. <source>Drugs</source>. <year>2007</year>;<volume>67</volume>: <fpage>351</fpage>&#x02013;<lpage>368</lpage>. <?supplied-pmid 17335295?><pub-id pub-id-type="pmid">17335295</pub-id></mixed-citation></ref><ref id="pone.0155139.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Strateva</surname><given-names>T</given-names></name>, <name><surname>Yordanov</surname><given-names>D</given-names></name>. <article-title><italic>Pseudomonas aeruginosa</italic>&#x02014;a phenomenon of bacterial resistance</article-title>. <source>J Med Microbiol</source>. <year>2009</year>;<volume>58</volume>: <fpage>1133</fpage>&#x02013;<lpage>1148</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1099/jmm.0.009142-0">10.1099/jmm.0.009142-0</ext-link></comment>
<?supplied-pmid 19528173?><pub-id pub-id-type="pmid">19528173</pub-id></mixed-citation></ref><ref id="pone.0155139.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Falagas</surname><given-names>ME</given-names></name>, <name><surname>Rafailidis</surname><given-names>PI</given-names></name>, <name><surname>Matthaiou</surname><given-names>DK</given-names></name>. <article-title>Resistance to polymyxins: Mechanisms, frequency and treatment options</article-title>. <source>Drug Resist Updat</source>. <year>2010</year>;<volume>13</volume>: <fpage>132</fpage>&#x02013;<lpage>138</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.drup.2010.05.002">10.1016/j.drup.2010.05.002</ext-link></comment>
<?supplied-pmid 20843473?><pub-id pub-id-type="pmid">20843473</pub-id></mixed-citation></ref><ref id="pone.0155139.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Butler</surname><given-names>MS</given-names></name>, <name><surname>Blaskovich</surname><given-names>MA</given-names></name>, <name><surname>Cooper</surname><given-names>MA</given-names></name>. <article-title>Antibiotics in the clinical pipeline in 2013</article-title>. <source>J Antibiot</source>. <year>2013</year>;<volume>66</volume>: <fpage>571</fpage>&#x02013;<lpage>591</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ja.2013.86">10.1038/ja.2013.86</ext-link></comment>
<?supplied-pmid 24002361?><pub-id pub-id-type="pmid">24002361</pub-id></mixed-citation></ref><ref id="pone.0155139.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Liebens</surname><given-names>V</given-names></name>, <name><surname>Gerits</surname><given-names>E</given-names></name>, <name><surname>Knapen</surname><given-names>WJ</given-names></name>, <name><surname>Swings</surname><given-names>T</given-names></name>, <name><surname>Beullens</surname><given-names>S</given-names></name>, <name><surname>Steenackers</surname><given-names>HP</given-names></name>, <etal>et al</etal>
<article-title>Identification and characterization of an anti-pseudomonal dichlorocarbazol derivative displaying anti-biofilm activity</article-title>. <source>Bioorg Med Chem Lett</source>. <year>2014</year>;<volume>24</volume>: <fpage>5404</fpage>&#x02013;<lpage>5408</lpage>. <?supplied-pmid 25453797?><pub-id pub-id-type="pmid">25453797</pub-id></mixed-citation></ref><ref id="pone.0155139.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Thevissen</surname><given-names>K</given-names></name>, <name><surname>Marchand</surname><given-names>A</given-names></name>, <name><surname>Chaltin</surname><given-names>P</given-names></name>, <name><surname>Meert</surname><given-names>E</given-names></name>, <name><surname>Cammue</surname><given-names>B</given-names></name>. <article-title>Antifungal Carbazoles</article-title>. <source>Curr Med Chem</source>. <year>2009</year>;<volume>16</volume>: <fpage>2205</fpage>&#x02013;<lpage>2211</lpage>. <?supplied-pmid 19519387?><pub-id pub-id-type="pmid">19519387</pub-id></mixed-citation></ref><ref id="pone.0155139.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Gerits</surname><given-names>E</given-names></name>, <name><surname>Kuchar&#x000ed;kov&#x000e1;</surname><given-names>S</given-names></name>, <name><surname>Van Dijck</surname><given-names>P</given-names></name>, <name><surname>Erdtmann</surname><given-names>M</given-names></name>, <name><surname>Krona</surname><given-names>A</given-names></name>, <name><surname>L&#x000f6;venklev</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Antibacterial activity of a new broad-spectrum antibiotic covalently bound to titanium surfaces</article-title>. <source>J Orthop Res</source>. <year>2016</year>. In press.</mixed-citation></ref><ref id="pone.0155139.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>O&#x02019;Neill</surname><given-names>AJ</given-names></name>. <article-title><italic>Staphylococcus aureus</italic> SH1000 and 8325&#x02013;4: comparative genome sequences of key laboratory strains in <italic>staphylococcal</italic> research</article-title>. <source>Lett Appl Microbiol</source>. <year>2010</year>;<volume>51</volume>: <fpage>358</fpage>&#x02013;<lpage>361</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1472-765X.2010.02885.x">10.1111/j.1472-765X.2010.02885.x</ext-link></comment>
<?supplied-pmid 20618890?><pub-id pub-id-type="pmid">20618890</pub-id></mixed-citation></ref><ref id="pone.0155139.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>DG</given-names></name>, <name><surname>Urbach</surname><given-names>JM</given-names></name>, <name><surname>Wu</surname><given-names>G</given-names></name>, <name><surname>Liberati</surname><given-names>NT</given-names></name>, <name><surname>Feinbaum</surname><given-names>RL</given-names></name>, <name><surname>Miyata</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Genomic analysis reveals that <italic>Pseudomonas aeruginosa</italic> virulence is combinatorial</article-title>. <source>Genome Biol</source>. <year>2006</year>;<volume>7</volume>: <fpage>R90</fpage>
<?supplied-pmid 17038190?><pub-id pub-id-type="pmid">17038190</pub-id></mixed-citation></ref><ref id="pone.0155139.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Liebens</surname><given-names>V</given-names></name>, <name><surname>Defraine</surname><given-names>V</given-names></name>, <name><surname>Van der Leyden</surname><given-names>A</given-names></name>, <name><surname>De Groote</surname><given-names>VN</given-names></name>, <name><surname>Fierro</surname><given-names>C</given-names></name>, <name><surname>Beullens</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>A putative de-N-acetylase of the PIG-L superfamily affects fluoroquinolone tolerance in <italic>Pseudomonas aeruginosa</italic></article-title>. <source>Pathog Dis</source>. <year>2014</year>;<volume>71</volume>: <fpage>39</fpage>&#x02013;<lpage>54</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/2049-632X.12174">10.1111/2049-632X.12174</ext-link></comment>
<?supplied-pmid 24692291?><pub-id pub-id-type="pmid">24692291</pub-id></mixed-citation></ref><ref id="pone.0155139.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Randall</surname><given-names>CP</given-names></name>, <name><surname>Mariner</surname><given-names>KR</given-names></name>, <name><surname>Chopra</surname><given-names>I</given-names></name>, <name><surname>O&#x02019;Neill</surname><given-names>AJ</given-names></name>. <article-title>The target of daptomycin is absent from <italic>Escherichia coli</italic> and other gram-negative pathogens</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2013</year>;<volume>57</volume>: <fpage>637</fpage>&#x02013;<lpage>639</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.02005-12">10.1128/AAC.02005-12</ext-link></comment>
<?supplied-pmid 23114759?><pub-id pub-id-type="pmid">23114759</pub-id></mixed-citation></ref><ref id="pone.0155139.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Yaraksa</surname><given-names>N</given-names></name>, <name><surname>Anunthawan</surname><given-names>T</given-names></name>, <name><surname>Theansungnoen</surname><given-names>T</given-names></name>, <name><surname>Daduang</surname><given-names>S</given-names></name>, <name><surname>Araki</surname><given-names>T</given-names></name>, <name><surname>Dhiravisit</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Design and synthesis of cationic antibacterial peptide based on Leucrocin I sequence, antibacterial peptide from crocodile (<italic>Crocodylus siamensis</italic>) white blood cell extracts</article-title>. <source>J Antibiot</source>. <year>2014</year>;<volume>67</volume>: <fpage>205</fpage>&#x02013;<lpage>212</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ja.2013.114">10.1038/ja.2013.114</ext-link></comment>
<?supplied-pmid 24192554?><pub-id pub-id-type="pmid">24192554</pub-id></mixed-citation></ref><ref id="pone.0155139.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Yan</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>K</given-names></name>, <name><surname>Dang</surname><given-names>W</given-names></name>, <name><surname>Chen</surname><given-names>R</given-names></name>, <name><surname>Xie</surname><given-names>J</given-names></name>, <name><surname>Zhang</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Two hits are better than one: membrane-active and DNA binding-related double-action mechanism of NK-18, a novel antimicrobial peptide derived from mammalian NK-lysin</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2013</year>;<volume>57</volume>: <fpage>220</fpage>&#x02013;<lpage>228</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.01619-12">10.1128/AAC.01619-12</ext-link></comment>
<?supplied-pmid 23089755?><pub-id pub-id-type="pmid">23089755</pub-id></mixed-citation></ref><ref id="pone.0155139.ref024"><label>24</label><mixed-citation publication-type="other">Andrews S. FastQC: a quality control tool for high throughput sequence data. 2010. Available: <ext-link ext-link-type="uri" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc">http://www.bioinformatics.babraham.ac.uk/projects/fastqc</ext-link>.</mixed-citation></ref><ref id="pone.0155139.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Anders</surname><given-names>S</given-names></name>, <name><surname>Pyl</surname><given-names>PT</given-names></name>, <name><surname>Huber</surname><given-names>W</given-names></name>. <article-title>HTSeq&#x02014;A Python framework to work with high-throughput sequencing data</article-title>. <source>Bioinformatics</source>. <year>2014</year>;<volume>31</volume>: <fpage>166</fpage>&#x02013;<lpage>169</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bioinformatics/btu638">10.1093/bioinformatics/btu638</ext-link></comment>
<?supplied-pmid 25260700?><pub-id pub-id-type="pmid">25260700</pub-id></mixed-citation></ref><ref id="pone.0155139.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Love</surname><given-names>MI</given-names></name>, <name><surname>Huber</surname><given-names>W</given-names></name>, <name><surname>Anders</surname><given-names>S</given-names></name>. <article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source>Genome Biol</source>. <year>2014</year>;<volume>15</volume>: <fpage>550</fpage>
<?supplied-pmid 25516281?><pub-id pub-id-type="pmid">25516281</pub-id></mixed-citation></ref><ref id="pone.0155139.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>De Maeyer</surname><given-names>D</given-names></name>, <name><surname>Weytjens</surname><given-names>B</given-names></name>, <name><surname>Renkens</surname><given-names>J</given-names></name>, <name><surname>De Raedt</surname><given-names>L</given-names></name>, <name><surname>Marchal</surname><given-names>K</given-names></name>. <article-title>PheNetic: network-based interpretation of molecular profiling data</article-title>. <source>Nucleic Acids Res</source>. <year>2015</year>;<volume>43</volume>: <fpage>W244</fpage>&#x02013;<lpage>250</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/gkv347">10.1093/nar/gkv347</ext-link></comment>
<?supplied-pmid 25878035?><pub-id pub-id-type="pmid">25878035</pub-id></mixed-citation></ref><ref id="pone.0155139.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Jensen</surname><given-names>LJ</given-names></name>, <name><surname>Kuhn</surname><given-names>M</given-names></name>, <name><surname>Stark</surname><given-names>M</given-names></name>, <name><surname>Chaffron</surname><given-names>S</given-names></name>, <name><surname>Creevey</surname><given-names>C</given-names></name>, <name><surname>Muller</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>STRING 8&#x02014;a global view on proteins and their functional interactions in 630 organisms</article-title>. <source>Nucleic Acids Res</source>. <year>2009</year>;<volume>37</volume>: <fpage>D412</fpage>&#x02013;<lpage>416</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/gkn760">10.1093/nar/gkn760</ext-link></comment>
<?supplied-pmid 18940858?><pub-id pub-id-type="pmid">18940858</pub-id></mixed-citation></ref><ref id="pone.0155139.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Kanehisa</surname><given-names>M</given-names></name>, <name><surname>Goto</surname><given-names>S</given-names></name>. <article-title>KEGG: Kyoto Encyclopedia of Genes and Genomes</article-title>. <source>Nucleic Acids Res</source>. <year>2000</year>;<volume>28</volume>: <fpage>27</fpage>&#x02013;<lpage>30</lpage>. <?supplied-pmid 10592173?><pub-id pub-id-type="pmid">10592173</pub-id></mixed-citation></ref><ref id="pone.0155139.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Gal&#x000e1;n-V&#x000e1;squez</surname><given-names>E</given-names></name>, <name><surname>Luna</surname><given-names>B</given-names></name>, <name><surname>Mart&#x000ed;nez-Antonio</surname><given-names>A</given-names></name>. <article-title>The regulatory network of <italic>Pseudomonas aeruginosa</italic></article-title>. <source>Microb Inform Exp</source>. <year>2011</year>;<volume>1</volume>: <fpage>3</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/2042-5783-1-3">10.1186/2042-5783-1-3</ext-link></comment>
<?supplied-pmid 22587778?><pub-id pub-id-type="pmid">22587778</pub-id></mixed-citation></ref><ref id="pone.0155139.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Aziz</surname><given-names>RK</given-names></name>, <name><surname>Bartels</surname><given-names>D</given-names></name>, <name><surname>Best</surname><given-names>AA</given-names></name>, <name><surname>DeJongh</surname><given-names>M</given-names></name>, <name><surname>Disz</surname><given-names>T</given-names></name>, <name><surname>Edwards</surname><given-names>RA</given-names></name>, <etal>et al</etal>
<article-title>The RAST Server: rapid annotations using subsystems technology</article-title>. <source>BMC Genomics</source>. <year>2008</year>;<volume>9</volume>: <fpage>75</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-2164-9-75">10.1186/1471-2164-9-75</ext-link></comment>
<?supplied-pmid 18261238?><pub-id pub-id-type="pmid">18261238</pub-id></mixed-citation></ref><ref id="pone.0155139.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Smoot</surname><given-names>ME</given-names></name>, <name><surname>Ono</surname><given-names>K</given-names></name>, <name><surname>Ruscheinski</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>PL</given-names></name>, <name><surname>Ideker</surname><given-names>T</given-names></name>. <article-title>Cytoscape 2.8: new features for data integration and network visualization</article-title>. <source>Bioinformatics</source>. <year>2011</year>;<volume>27</volume>: <fpage>431</fpage>&#x02013;<lpage>432</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bioinformatics/btq675">10.1093/bioinformatics/btq675</ext-link></comment>
<?supplied-pmid 21149340?><pub-id pub-id-type="pmid">21149340</pub-id></mixed-citation></ref><ref id="pone.0155139.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Maere</surname><given-names>S</given-names></name>, <name><surname>Heymans</surname><given-names>K</given-names></name>, <name><surname>Kuiper</surname><given-names>M</given-names></name>. <article-title>BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks</article-title>. <source>Bioinformatics</source>. <year>2005</year>;<volume>21</volume>: <fpage>3448</fpage>&#x02013;<lpage>3449</lpage>. <?supplied-pmid 15972284?><pub-id pub-id-type="pmid">15972284</pub-id></mixed-citation></ref><ref id="pone.0155139.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Bairoch</surname><given-names>A</given-names></name>, <name><surname>Apweiler</surname><given-names>R</given-names></name>, <name><surname>Wu</surname><given-names>CH</given-names></name>, <name><surname>Barker</surname><given-names>WC</given-names></name>, <name><surname>Boeckmann</surname><given-names>B</given-names></name>, <name><surname>Ferro</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>The Universal Protein Resource (UniProt)</article-title>. <source>Nucleic Acids Res</source>. <year>2005</year>;<volume>33</volume>: <fpage>D154</fpage>&#x02013;<lpage>159</lpage>. <?supplied-pmid 15608167?><pub-id pub-id-type="pmid">15608167</pub-id></mixed-citation></ref><ref id="pone.0155139.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Liberati</surname><given-names>NT</given-names></name>, <name><surname>Urbach</surname><given-names>JM</given-names></name>, <name><surname>Miyata</surname><given-names>S</given-names></name>, <name><surname>Lee</surname><given-names>DG</given-names></name>, <name><surname>Drenkard</surname><given-names>E</given-names></name>, <name><surname>Wu</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>An ordered, nonredundant library of <italic>Pseudomonas aeruginosa</italic> strain PA14 transposon insertion mutants</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2006</year>;<volume>103</volume>: <fpage>2833</fpage>&#x02013;<lpage>2838</lpage>. <?supplied-pmid 16477005?><pub-id pub-id-type="pmid">16477005</pub-id></mixed-citation></ref><ref id="pone.0155139.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Hilliard</surname><given-names>JJ</given-names></name>, <name><surname>Goldschmidt</surname><given-names>RM</given-names></name>, <name><surname>Licata</surname><given-names>L</given-names></name>, <name><surname>Baum</surname><given-names>EZ</given-names></name>, <name><surname>Bush</surname><given-names>K</given-names></name>. <article-title>Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems</article-title>. <source>Antimicrob Agents Chemother</source>. <year>1999</year>;<volume>43</volume>: <fpage>1693</fpage>&#x02013;<lpage>1699</lpage>. <?supplied-pmid 10390224?><pub-id pub-id-type="pmid">10390224</pub-id></mixed-citation></ref><ref id="pone.0155139.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Oliva</surname><given-names>B</given-names></name>, <name><surname>Miller</surname><given-names>K</given-names></name>, <name><surname>Caggiano</surname><given-names>N</given-names></name>, <name><surname>O&#x02019;Neill</surname><given-names>AJ</given-names></name>, <name><surname>Cuny</surname><given-names>GD</given-names></name>, <name><surname>Hoemann</surname><given-names>MZ</given-names></name>, <etal>et al</etal>
<article-title>Biological properties of novel antistaphylococcal quinoline-indole agents</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2003</year>;<volume>47</volume>: <fpage>458</fpage>&#x02013;<lpage>466</lpage>. <?supplied-pmid 12543644?><pub-id pub-id-type="pmid">12543644</pub-id></mixed-citation></ref><ref id="pone.0155139.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Hobbs</surname><given-names>JK</given-names></name>, <name><surname>Miller</surname><given-names>K</given-names></name>, <name><surname>O&#x02019;Neill</surname><given-names>AJ</given-names></name>, <name><surname>Chopra</surname><given-names>I</given-names></name>. <article-title>Consequences of daptomycin-mediated membrane damage in <italic>Staphylococcus aureus</italic></article-title>. <source>J Antimicrob Chemother</source>. <year>2008</year>;<volume>62</volume>: <fpage>1003</fpage>&#x02013;<lpage>1008</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jac/dkn321">10.1093/jac/dkn321</ext-link></comment>
<?supplied-pmid 18669516?><pub-id pub-id-type="pmid">18669516</pub-id></mixed-citation></ref><ref id="pone.0155139.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Ooi</surname><given-names>N</given-names></name>, <name><surname>Miller</surname><given-names>K</given-names></name>, <name><surname>Hobbs</surname><given-names>J</given-names></name>, <name><surname>Rhys-Williams</surname><given-names>W</given-names></name>, <name><surname>Love</surname><given-names>W</given-names></name>, <name><surname>Chopra</surname><given-names>I</given-names></name>. <article-title>XF-73, a novel antistaphylococcal membrane-active agent with rapid bactericidal activity</article-title>. <source>J Antimicrob Chemother</source>. <year>2009</year>;<volume>64</volume>: <fpage>735</fpage>&#x02013;<lpage>740</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jac/dkp299">10.1093/jac/dkp299</ext-link></comment>
<?supplied-pmid 19689976?><pub-id pub-id-type="pmid">19689976</pub-id></mixed-citation></ref><ref id="pone.0155139.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Roth</surname><given-names>BL</given-names></name>, <name><surname>Poot</surname><given-names>M</given-names></name>, <name><surname>Yue</surname><given-names>ST</given-names></name>, <name><surname>Millard</surname><given-names>PJ</given-names></name>. <article-title>Bacterial viability and antibiotic susceptibility testing with SYTOX green nucleic acid stain</article-title>. <source>Appl Environ Microbiol</source>. <year>1997</year>;<volume>63</volume>: <fpage>2421</fpage>&#x02013;<lpage>2431</lpage>. <?supplied-pmid 9172364?><pub-id pub-id-type="pmid">9172364</pub-id></mixed-citation></ref><ref id="pone.0155139.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Nikaido</surname><given-names>H</given-names></name>. <article-title>Molecular basis of bacterial outer membrane permeability revisited</article-title>. <source>Microbiol Mol Biol Rev</source>. <year>2003</year>;<volume>67</volume>: <fpage>593</fpage>&#x02013;<lpage>656</lpage>. <?supplied-pmid 14665678?><pub-id pub-id-type="pmid">14665678</pub-id></mixed-citation></ref><ref id="pone.0155139.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Helander</surname><given-names>IM</given-names></name>, <name><surname>Mattila-Sandholm</surname><given-names>T</given-names></name>. <article-title>Fluorometric assessment of Gram-negative bacterial permeabilization</article-title>. <source>J Appl Microbiol</source>. <year>2000</year>;<volume>88</volume>: <fpage>213</fpage>&#x02013;<lpage>219</lpage>. <?supplied-pmid 10735988?><pub-id pub-id-type="pmid">10735988</pub-id></mixed-citation></ref><ref id="pone.0155139.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Andries</surname><given-names>K</given-names></name>, <name><surname>Verhasselt</surname><given-names>P</given-names></name>, <name><surname>Guillemont</surname><given-names>J</given-names></name>, <name><surname>G&#x000f6;hlmann</surname><given-names>HW</given-names></name>, <name><surname>Neefs</surname><given-names>JM</given-names></name>, <name><surname>Winkler</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>A diarylquinoline drug active on the ATP synthase of <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Science</source>. <year>2005</year>;<volume>14</volume>: <fpage>223</fpage>&#x02013;<lpage>227</lpage>.<pub-id pub-id-type="pmid">15591164</pub-id></mixed-citation></ref><ref id="pone.0155139.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Pethe</surname><given-names>K</given-names></name>, <name><surname>Sequeira</surname><given-names>PC</given-names></name>, <name><surname>Agarwalla</surname><given-names>S</given-names></name>, <name><surname>Rhee</surname><given-names>K</given-names></name>, <name><surname>Kuhen</surname><given-names>K</given-names></name>, <name><surname>Phong</surname><given-names>WY</given-names></name>, <etal>et al</etal>
<article-title>A chemical genetic screen in <italic>Mycobacterium tuberculosis</italic> identifies carbon-source-dependent growth inhibitors devoid of <italic>in vivo</italic> efficacy</article-title>. <source>Nat Commun</source>. <year>2010</year>;<volume>1</volume>: <fpage>57</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ncomms1060">10.1038/ncomms1060</ext-link></comment>
<?supplied-pmid 20975714?><pub-id pub-id-type="pmid">20975714</pub-id></mixed-citation></ref><ref id="pone.0155139.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Srinivas</surname><given-names>N</given-names></name>, <name><surname>Jetter</surname><given-names>P</given-names></name>, <name><surname>Ueberbacher</surname><given-names>BJ</given-names></name>, <name><surname>Werneburg</surname><given-names>M</given-names></name>, <name><surname>Zerbe</surname><given-names>K</given-names></name>, <name><surname>Steinmann</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Peptidomimetic antibiotics target outer-membrane biogenesis in <italic>Pseudomonas aeruginosa</italic></article-title>. <source>Science</source>. <year>2010</year>;<volume>327</volume>: <fpage>1010</fpage>&#x02013;<lpage>1013</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1182749">10.1126/science.1182749</ext-link></comment>
<?supplied-pmid 20167788?><pub-id pub-id-type="pmid">20167788</pub-id></mixed-citation></ref><ref id="pone.0155139.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Grzegorzewicz</surname><given-names>AE</given-names></name>, <name><surname>Pham</surname><given-names>H</given-names></name>, <name><surname>Gundi</surname><given-names>VA</given-names></name>, <name><surname>Scherman</surname><given-names>MS</given-names></name>, <name><surname>North</surname><given-names>EJ</given-names></name>, <name><surname>Hess</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>Inhibition of mycolic acid transport across the <italic>Mycobacterium tuberculosis</italic> plasma membrane</article-title>. <source>Nat Chem Biol</source>. <year>2012</year>;<volume>8</volume>: <fpage>334</fpage>&#x02013;<lpage>341</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nchembio.794">10.1038/nchembio.794</ext-link></comment>
<?supplied-pmid 22344175?><pub-id pub-id-type="pmid">22344175</pub-id></mixed-citation></ref><ref id="pone.0155139.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Purssell</surname><given-names>A</given-names></name>, <name><surname>Poole</surname><given-names>K</given-names></name>. <article-title>Functional characterization of the NfxB repressor of the mexCD-oprJ multidrug efflux operon of <italic>Pseudomonas aeruginosa</italic></article-title>. <source>Microbiology</source>. <year>2013</year>;<volume>159</volume>: <fpage>2058</fpage>&#x02013;<lpage>20773</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1099/mic.0.069286-0">10.1099/mic.0.069286-0</ext-link></comment>
<?supplied-pmid 23924707?><pub-id pub-id-type="pmid">23924707</pub-id></mixed-citation></ref><ref id="pone.0155139.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Clementz</surname><given-names>T</given-names></name>, <name><surname>Bednarski</surname><given-names>JJ</given-names></name>, <name><surname>Raetz</surname><given-names>CR</given-names></name>. <article-title>Function of the <italic>htrB</italic> high temperature requirement gene of Escherichia coli in the acylation of Lipid A</article-title>. <source>J Biol Chem</source>. <year>1996</year>;<volume>271</volume>: <fpage>12095</fpage>&#x02013;<lpage>12102</lpage>. <?supplied-pmid 8662613?><pub-id pub-id-type="pmid">8662613</pub-id></mixed-citation></ref><ref id="pone.0155139.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Winsor</surname><given-names>GL</given-names></name>, <name><surname>Lam</surname><given-names>DKW</given-names></name>, <name><surname>Fleming</surname><given-names>L</given-names></name>, <name><surname>Lo</surname><given-names>R</given-names></name>, <name><surname>Whiteside</surname><given-names>MD</given-names></name>, <name><surname>Yu</surname><given-names>NY</given-names></name>, <etal>et al</etal>
<article-title>Pseudomonas Genome Database: improved comparative analysis and population genomics capability for Pseudomonas genomes</article-title>. <source>Nucleic Acids Res</source>. <year>2011</year>;<volume>39</volume>: <fpage>D596</fpage>&#x02013;<lpage>600</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/gkq869">10.1093/nar/gkq869</ext-link></comment>
<?supplied-pmid 20929876?><pub-id pub-id-type="pmid">20929876</pub-id></mixed-citation></ref><ref id="pone.0155139.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>de Boer</surname><given-names>PA</given-names></name>, <name><surname>Crossley</surname><given-names>RE</given-names></name>, <name><surname>Rothfield</surname><given-names>LI</given-names></name>. <article-title>A division inhibitor and a topological specificity factor coded for by the minicell locus determine proper placement of the division septum in <italic>E</italic>. <italic>coli</italic></article-title>. <source>Cell</source>. <year>1989</year>;<volume>56</volume>: <fpage>641</fpage>&#x02013;<lpage>649</lpage>. <?supplied-pmid 2645057?><pub-id pub-id-type="pmid">2645057</pub-id></mixed-citation></ref><ref id="pone.0155139.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Baba</surname><given-names>T</given-names></name>, <name><surname>Ara</surname><given-names>T</given-names></name>, <name><surname>Hasegawa</surname><given-names>M</given-names></name>, <name><surname>Takai</surname><given-names>Y</given-names></name>, <name><surname>Okumura</surname><given-names>Y</given-names></name>, <name><surname>Baba</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Construction of <italic>Escherichia coli</italic> K-12 in-frame, single-gene knockout mutants: the Keio collection</article-title>. <source>Mol Syst Biol</source>. <year>2006</year>;<volume>2</volume>: <fpage>2006.0008</fpage>.</mixed-citation></ref><ref id="pone.0155139.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Ling</surname><given-names>LL</given-names></name>, <name><surname>Schneider</surname><given-names>T</given-names></name>, <name><surname>Peoples</surname><given-names>AJ</given-names></name>, <name><surname>Spoering</surname><given-names>AL</given-names></name>, <name><surname>Engels</surname><given-names>I</given-names></name>, <name><surname>Conlon</surname><given-names>BP</given-names></name>, <etal>et al</etal>
<article-title>A new antibiotic kills pathogens without detectable resistance</article-title>. <source>Nature</source>. <year>2015</year>;<volume>517</volume>: <fpage>455</fpage>&#x02013;<lpage>459</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature14098">10.1038/nature14098</ext-link></comment>
<?supplied-pmid 25561178?><pub-id pub-id-type="pmid">25561178</pub-id></mixed-citation></ref><ref id="pone.0155139.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>LaPlante</surname><given-names>KL</given-names></name>, <name><surname>Rybak</surname><given-names>MJ</given-names></name>. <article-title>Impact of high-inoculum <italic>Staphylococcus aureus</italic> on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an <italic>in vitro</italic> pharmacodynamic model</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2004</year>;<volume>48</volume>: <fpage>4665</fpage>&#x02013;<lpage>4672</lpage>. <?supplied-pmid 15561842?><pub-id pub-id-type="pmid">15561842</pub-id></mixed-citation></ref><ref id="pone.0155139.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Tam</surname><given-names>VH</given-names></name>, <name><surname>Schilling</surname><given-names>AN</given-names></name>, <name><surname>Nikolaou</surname><given-names>M</given-names></name>. <article-title>Modelling time-kill studies to discern the pharmacodynamics of meropenem</article-title>. <source>J Antimicrob Chemother</source>. <year>2005</year>;<volume>55</volume>: <fpage>699</fpage>&#x02013;<lpage>706</lpage>. <?supplied-pmid 15772138?><pub-id pub-id-type="pmid">15772138</pub-id></mixed-citation></ref><ref id="pone.0155139.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Tam</surname><given-names>VH</given-names></name>, <name><surname>Schilling</surname><given-names>AN</given-names></name>, <name><surname>Vo</surname><given-names>G</given-names></name>, <name><surname>Kabbara</surname><given-names>S</given-names></name>, <name><surname>Kwa</surname><given-names>AL</given-names></name>, <name><surname>Wiederhold</surname><given-names>NP</given-names></name>, <etal>et al</etal>
<article-title>Pharmacodynamics of Polymyxin B against <italic>Pseudomonas aeruginosa</italic></article-title>. <source>Antimicrob Agents Chemother</source>. <year>2005</year>;<volume>49</volume>: <fpage>3624</fpage>&#x02013;<lpage>3630</lpage>. <?supplied-pmid 16127031?><pub-id pub-id-type="pmid">16127031</pub-id></mixed-citation></ref><ref id="pone.0155139.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Bulitta</surname><given-names>JB</given-names></name>, <name><surname>Yang</surname><given-names>JC</given-names></name>, <name><surname>Yohonn</surname><given-names>L</given-names></name>, <name><surname>Ly</surname><given-names>NS</given-names></name>, <name><surname>Brown</surname><given-names>SV</given-names></name>, <name><surname>D&#x02019;Hondt</surname><given-names>RE</given-names></name>, <etal>et al</etal>
<article-title>Attenuation of colistin bactericidal activity by high inoculum of <italic>Pseudomonas aeruginosa</italic> characterized by a new mechanism-based population pharmacodynamic model</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2010</year>;<volume>54</volume>: <fpage>2051</fpage>&#x02013;<lpage>2062</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.00881-09">10.1128/AAC.00881-09</ext-link></comment>
<?supplied-pmid 20211900?><pub-id pub-id-type="pmid">20211900</pub-id></mixed-citation></ref><ref id="pone.0155139.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Hurdle</surname><given-names>JG</given-names></name>, <name><surname>O&#x02019;Neill</surname><given-names>AJ</given-names></name>, <name><surname>Chopra</surname><given-names>I</given-names></name>, <name><surname>Lee</surname><given-names>RE</given-names></name>. <article-title>Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections</article-title>. <source>Nat Rev Microbiol</source>. <year>2011</year>;<volume>9</volume>: <fpage>62</fpage>&#x02013;<lpage>75</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrmicro2474">10.1038/nrmicro2474</ext-link></comment>
<?supplied-pmid 21164535?><pub-id pub-id-type="pmid">21164535</pub-id></mixed-citation></ref><ref id="pone.0155139.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Stickland</surname><given-names>HG</given-names></name>, <name><surname>Davenport</surname><given-names>PW</given-names></name>, <name><surname>Lilley</surname><given-names>KS</given-names></name>, <name><surname>Griffin</surname><given-names>JL</given-names></name>, <name><surname>Welch</surname><given-names>M</given-names></name>. <article-title>Mutation of <italic>nfxB</italic> causes global changes in the physiology and metabolism of <italic>Pseudomonas aeruginosa</italic></article-title>. <source>J Proteome Res</source>. <year>2010</year>;<volume>9</volume>: <fpage>2957</fpage>&#x02013;<lpage>2967</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1021/pr9011415">10.1021/pr9011415</ext-link></comment>
<?supplied-pmid 20373734?><pub-id pub-id-type="pmid">20373734</pub-id></mixed-citation></ref><ref id="pone.0155139.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>XZ</given-names></name>, <name><surname>Nikaido</surname><given-names>H</given-names></name>. <article-title>Efflux-mediated drug resistance in bacteria</article-title>. <source>Drugs</source>. <year>2004</year>;<volume>64</volume>: <fpage>159</fpage>&#x02013;<lpage>204</lpage>. <?supplied-pmid 14717618?><pub-id pub-id-type="pmid">14717618</pub-id></mixed-citation></ref><ref id="pone.0155139.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Boyd</surname><given-names>A</given-names></name>, <name><surname>Chakrabarty</surname><given-names>AM</given-names></name>. <article-title>1995. <italic>Pseudomonas aeruginosa</italic> biofilms: role of the alginate exopolysaccharide</article-title>. <source>J Ind Microbiol</source>. <year>1995</year>;<volume>15</volume>: <fpage>162</fpage>&#x02013;<lpage>168</lpage>. <?supplied-pmid 8519473?><pub-id pub-id-type="pmid">8519473</pub-id></mixed-citation></ref><ref id="pone.0155139.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Blake</surname><given-names>KL</given-names></name>, <name><surname>O&#x02019;Neill</surname><given-names>AJ</given-names></name>. <article-title>Transposon library screening for identification of genetic loci participating in intrinsic susceptibility and acquired resistance to antistaphylococcal agents</article-title>. <source>J Antimicrob Chemother</source>. <year>2013</year>;<volume>68</volume>: <fpage>12</fpage>&#x02013;<lpage>16</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/jac/dks373">10.1093/jac/dks373</ext-link></comment>
<?supplied-pmid 23045225?><pub-id pub-id-type="pmid">23045225</pub-id></mixed-citation></ref><ref id="pone.0155139.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Bollenbach</surname><given-names>T</given-names></name>. <article-title>Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution</article-title>. <source>Curr Opin Microbiol</source>. <year>2015</year>;<volume>27</volume>: <fpage>1</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.mib.2015.05.008">10.1016/j.mib.2015.05.008</ext-link></comment>
<?supplied-pmid 26042389?><pub-id pub-id-type="pmid">26042389</pub-id></mixed-citation></ref><ref id="pone.0155139.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Marr</surname><given-names>AK</given-names></name>, <name><surname>Gooderham</surname><given-names>WJ</given-names></name>, <name><surname>Hancock</surname><given-names>RE</given-names></name>. <article-title>Antibacterial peptides for therapeutic use: obstacles and realistic outlook</article-title>. <source>Curr Opin Pharmacol</source>. <year>2006</year>;<volume>6</volume>:<fpage>468</fpage>&#x02013;<lpage>472</lpage>. <?supplied-pmid 16890021?><pub-id pub-id-type="pmid">16890021</pub-id></mixed-citation></ref><ref id="pone.0155139.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Wright</surname><given-names>PM</given-names></name>, <name><surname>Seiple</surname><given-names>IB</given-names></name>, <name><surname>Myers</surname><given-names>AG</given-names></name>. <article-title>The evolving role of chemical synthesis in antibacterial drug discovery</article-title>. <source>Angew Chem Int Ed Engl</source>. <year>2014</year>;<volume>18</volume>: <fpage>8840</fpage>&#x02013;<lpage>8869</lpage>.<pub-id pub-id-type="pmid">24990531</pub-id></mixed-citation></ref><ref id="pone.0155139.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Steenackers</surname><given-names>H</given-names></name>, <name><surname>Dubey</surname><given-names>A</given-names></name>, <name><surname>Robijns</surname><given-names>S</given-names></name>, <name><surname>Ermolat&#x02019;ev</surname><given-names>D</given-names></name>, <name><surname>Delattin</surname><given-names>N</given-names></name>, <name><surname>Dovgan</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Evaluation of the toxicity of 5-aryl-2-aminoimidazole-based biofilm inhibitors against eukaryotic cell lines, bone cells and the nematode <italic>Caenorhabditis elegans</italic></article-title>. <source>Molecules</source>. <year>2014</year>;<volume>19</volume>: <fpage>16707</fpage>&#x02013;<lpage>16723</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3390/molecules191016707">10.3390/molecules191016707</ext-link></comment>
<?supplied-pmid 25325155?><pub-id pub-id-type="pmid">25325155</pub-id></mixed-citation></ref></ref-list></back></article>